The Cost Effectiveness of Polar Chips

So right now we have a 6.5% progression free survival benefit. Let's say the benefit sustains, but it's not 6.5%. So five-year follow-up, it's 5% benefit on PFS. How would that factor in the model? Yeah, so I think a couple things about that. If there really was no overall survival, meaning that getting all these downstream therapies had no impact on mortality whatsoever,. That's certainly a different scenario than if the PFS remains different. It does lead to some differences in mortality because of the toxicity of transplant or even increased mortality with relapse.